Despite inauspicious beginnings, more than 400 therapeutic mAbs entered commercially sponsored clinical development during this time, with anticancer mAbs comprising approximately half of the total1.

• 除去失败的序曲，四百多种治疗性单抗已经进入由药商发起的临床实验中，其中一半以上为抗肿瘤单抗。